NZ526236A - Isoindolin-1-one glucokinase activators and their use in pharmaceutical compositions for the treatment of type II diabetes - Google Patents

Isoindolin-1-one glucokinase activators and their use in pharmaceutical compositions for the treatment of type II diabetes

Info

Publication number
NZ526236A
NZ526236A NZ526236A NZ52623601A NZ526236A NZ 526236 A NZ526236 A NZ 526236A NZ 526236 A NZ526236 A NZ 526236A NZ 52623601 A NZ52623601 A NZ 52623601A NZ 526236 A NZ526236 A NZ 526236A
Authority
NZ
New Zealand
Prior art keywords
isoindolin
diabetes
treatment
type
pharmaceutical compositions
Prior art date
Application number
NZ526236A
Other languages
English (en)
Inventor
Kevin Richard Guertin
Original Assignee
F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F filed Critical F
Publication of NZ526236A publication Critical patent/NZ526236A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
NZ526236A 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators and their use in pharmaceutical compositions for the treatment of type II diabetes NZ526236A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13
PCT/EP2001/014404 WO2002048106A2 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators

Publications (1)

Publication Number Publication Date
NZ526236A true NZ526236A (en) 2004-12-24

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ526236A NZ526236A (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators and their use in pharmaceutical compositions for the treatment of type II diabetes

Country Status (35)

Country Link
US (1) US6482951B2 (https=)
EP (1) EP1349856B1 (https=)
JP (1) JP4021766B2 (https=)
KR (1) KR100520651B1 (https=)
CN (1) CN1247574C (https=)
AT (1) ATE297922T1 (https=)
AU (2) AU3841502A (https=)
BG (1) BG107903A (https=)
BR (1) BR0116169A (https=)
CA (1) CA2430579C (https=)
CY (1) CY1105587T1 (https=)
CZ (1) CZ20031882A3 (https=)
DE (1) DE60111570T2 (https=)
DK (1) DK1349856T3 (https=)
EG (1) EG24358A (https=)
ES (1) ES2243578T3 (https=)
HR (1) HRP20030450B1 (https=)
HU (1) HUP0400587A3 (https=)
IL (2) IL156264A0 (https=)
MA (1) MA26973A1 (https=)
MX (1) MXPA03005170A (https=)
MY (1) MY136741A (https=)
NO (1) NO325810B1 (https=)
NZ (1) NZ526236A (https=)
PA (1) PA8534601A1 (https=)
PE (1) PE20020593A1 (https=)
PL (1) PL366006A1 (https=)
PT (1) PT1349856E (https=)
RS (1) RS50933B (https=)
RU (1) RU2249590C2 (https=)
SI (1) SI1349856T1 (https=)
SK (1) SK8732003A3 (https=)
TW (1) TWI294876B (https=)
UY (1) UY27069A1 (https=)
WO (1) WO2002048106A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2309956C2 (ru) 2002-10-03 2007-11-10 Ф.Хоффманн-Ля Рош Аг Производные индол-3-карбоксамида в качестве активаторов глюкокиназы
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US7750020B2 (en) 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
AU2005229415B2 (en) * 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
CA2621227A1 (en) * 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
WO2007053662A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
WO2007053503A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
CA2627910A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007053657A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
KR20100110367A (ko) * 2008-01-24 2010-10-12 메르크 파텐트 게엠베하 당뇨병 치료를 위한 베타-아미노산 유도체들
SI2275414T1 (sl) 2008-04-28 2015-10-30 Kyorin Pharmaceutical Co., Ltd., Ciklopentilakrilamidni derivat
BRPI0912802A2 (pt) * 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
KR101258331B1 (ko) * 2008-09-11 2013-04-26 화이자 인코포레이티드 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
SI3004076T1 (sl) * 2013-05-27 2020-02-28 F. Hoffmann-La Roche Ag Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN116283717B (zh) * 2023-01-06 2025-04-08 暨南大学 一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (en) * 2023-05-02 2024-11-07 The Rockefeller University 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
CA2224062C (en) * 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
AU2001252270B2 (en) 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
AU778036B2 (en) 2000-05-08 2004-11-11 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators

Also Published As

Publication number Publication date
PT1349856E (pt) 2005-09-30
CY1105587T1 (el) 2010-07-28
CN1481382A (zh) 2004-03-10
HUP0400587A2 (hu) 2004-06-28
IL156264A0 (en) 2004-01-04
PE20020593A1 (es) 2002-07-06
MY136741A (en) 2008-11-28
NO20032674L (no) 2003-06-12
YU47703A (sh) 2006-05-25
MA26973A1 (fr) 2004-12-20
JP2004521095A (ja) 2004-07-15
EG24358A (en) 2009-03-04
IL156264A (en) 2010-11-30
KR100520651B1 (ko) 2005-10-11
RU2249590C2 (ru) 2005-04-10
HUP0400587A3 (en) 2011-03-28
UY27069A1 (es) 2002-07-31
DK1349856T3 (da) 2005-10-17
WO2002048106A2 (en) 2002-06-20
EP1349856A2 (en) 2003-10-08
EP1349856B1 (en) 2005-06-15
DE60111570D1 (de) 2005-07-21
BR0116169A (pt) 2003-12-23
HRP20030450A2 (en) 2005-04-30
TWI294876B (en) 2008-03-21
PL366006A1 (en) 2005-01-24
US6482951B2 (en) 2002-11-19
NO325810B1 (no) 2008-07-21
DE60111570T2 (de) 2006-05-11
WO2002048106A3 (en) 2002-11-28
HK1063314A1 (en) 2004-12-24
CA2430579A1 (en) 2002-06-20
CA2430579C (en) 2010-01-26
SI1349856T1 (en) 2005-10-31
SK8732003A3 (en) 2004-04-06
MXPA03005170A (es) 2003-09-22
US20020082260A1 (en) 2002-06-27
CZ20031882A3 (cs) 2003-12-17
CN1247574C (zh) 2006-03-29
ES2243578T3 (es) 2005-12-01
NO20032674D0 (no) 2003-06-12
RS50933B (sr) 2010-08-31
ATE297922T1 (de) 2005-07-15
AU2002238415B2 (en) 2007-01-04
KR20030064817A (ko) 2003-08-02
AU3841502A (en) 2002-06-24
BG107903A (bg) 2004-02-27
PA8534601A1 (es) 2002-08-26
JP4021766B2 (ja) 2007-12-12
HRP20030450B1 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
NZ526236A (en) Isoindolin-1-one glucokinase activators and their use in pharmaceutical compositions for the treatment of type II diabetes
NZ514025A (en) Compositions and methods for the modification of gene transcription
GB9922071D0 (en) Methods and means for modification of plant characteristics
IL193758A0 (en) Genetically engineered duckweed
EP1151085B8 (en) Nucleic acid molecules encoding alternansucrase
EP2186899A3 (en) Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP0289479A3 (en) Insect-resistant plants
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
CA2120514A1 (en) Synthetic dna sequence having enhanced insecticidal activity in maize
GB9902660D0 (en) Plant gene
CA2115049A1 (en) Dna sequences encoding gelonin polypeptide
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
TR200403501T2 (tr) Transgenik bitki ve metotları.
WO1996007749A3 (en) Methods and compositions for inhibiting production of replication competent virus
WO2002055658A3 (en) Identification and characterization of an anthocyanin mutant (ant1) in tomato
AU6198000A (en) Gene encoding short integuments and uses thereof
HUT63458A (en) Process for producing and using polypeptides participating in the biosynthesis of cobalamins and/or cobamides and dna sequences encoding them
AU8371501A (en) Manipulation of plant senescence using an MYB gene promoter and cytokinin biosyntyhesis genes
AU782261C (en) Novel glycosyltransferase genes
MXPA02012378A (es) Secuencias de nucleotidos y aminoacidos de factores de oocito para alterar el crecimiento folicular ovarico in vivo in vitro.
AP9200411A0 (en) Improvements in or relating to organic compounds.
WO2001002589A3 (en) Methods, compositions and genetic sequences for modulating flowering in plants, and plants genetically modified to flower early and tardily
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
WO2001090343A3 (en) Nucleotide sequences encoding ramosa 1 gene and methods of use for same
WO2001042447A3 (en) Modified minimal promoters

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)